---
title: "Zenas BioPharma Q2 FY26 net loss widens to $111.5 million; revenue rises to $1 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295786546.md"
description: "Zenas BioPharma reported a widened Q2 FY26 net loss of $111.5 million against $1 million in revenue, driven by increased R&D and G&A expenses. The company holds $673.9 million in cash and investments. Additionally, the FDA accepted obexelimab’s BLA for IgG4-RD, setting a PDUFA date of May 27, 2027."
datetime: "2026-08-13T11:04:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295786546.md)
  - [en](https://longbridge.com/en/news/295786546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295786546.md)
generator: "portal-rs"
---

# Zenas BioPharma Q2 FY26 net loss widens to $111.5 million; revenue rises to $1 million

-   Zenas posted Q2 2026 net loss of $111.5 million, widening from $52.2 million a year earlier. \* Revenue was $1 million, swinging from no revenue, tied to a development milestone under its Tenacia agreement for ZB005. \* R&D expense climbed to $62.9 million from $43 million, on higher clinical trial, regulatory, and personnel costs. \* G&A expense rose to $15.7 million from $12.1 million, reflecting higher headcount and pre-commercialization spending. \* FDA accepted obexelimab’s IgG4-RD BLA with a May 27, 2027 PDUFA date; cash and investments totaled $673.9 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9809447) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ZBIO.US](https://longbridge.com/en/quote/ZBIO.US.md)

## Related News & Research

- [Zenas Biopharma director Christy J. Oliger files initial beneficial ownership statement](https://longbridge.com/en/news/297823217.md)
- [Zenas Biopharma outlines autoimmune disease pipeline in corporate presentation](https://longbridge.com/en/news/297813603.md)
- [CPINV: Rental income up 12%, 100% occupancy, stable portfolio, and upgraded 2026 earnings guidance](https://longbridge.com/en/news/297809726.md)
- [12:54 ETDemotech, Inc.'s Perspective on Lawyer International - Legal 100 2026 Award](https://longbridge.com/en/news/297545724.md)
- [Ripple (XRP) Stock Price Forecast: Will It Reach $100 by 2030?](https://longbridge.com/en/news/297791005.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**